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Abstract 
Hypoxia/reoxygenation  (H/R)  reportedly
influences nitric oxide (NO) production and
NO synthase (NOS) expression in the heart.
Nonetheless, a number of works have shown
controversial  results  regarding  the  changes
that  the  cardiac  NO/NOS  system  undergoes
under  such  situations.  Therefore,  this  study
aims to clarify the behaviour of this system in
the hypoxic heart by investigating seven differ-
ent reoxygenation times. Wistar rats were sub-
mitted to H/R (hypoxia for 30 min; reoxygena-
tion of 0, 2, 12, 24, 48, 72 h, and 5 days) in a
novel approach to address the events provoked
by  assaults  under  such  circumstances.
Endothelial  and  inducible  NOS  (eNOS  and
iNOS) mRNA and protein expression, as well
as  enzymatic  activity  and  enzyme  location
were  determined.  NO  levels  were  indirectly
quantified  as  nitrate/nitrite,  and  other  S-
nitroso compounds (NOx), which would act as
NO-storage molecules. The results showed a
significant increase in eNOS mRNA, protein
and activity, as well as in NOx levels immedi-
ately  after  hypoxia,  while  iNOS  protein  and
activity  were  induced  throughout  the  reoxy-
genation period. These findings indicate that,
not only short-term hypoxia, but also the sub-
sequent reoxygenation period upregulate car-
diac NO/NOS system until at least 5 days after
the hypoxic stimulus, implying major involve-
ment of this system in the changes occurring
in the heart in response to H/R.
Introduction
Hypoxia  is  one  of  the  most  frequently
encountered types of stress in health and dis-
ease. The heart may be submitted to hypoxia
in many circumstances, including ischaemia,
haemorrhage,  pulmonary  diseases,  cardiac
arrest,  exposure  to  high  altitude,  and  other
cardiovascular problems. It has been suggest-
ed that nitric oxide (NO) plays a critical role in
modulating cardiac function during hypoxia.1
NO is synthesised from L-arginine by a group
of  hemoproteins  known  as  NO  synthases
(NOS). Three NOS isoforms have been classi-
cally  identified:2 endothelial  NOS  (eNOS),
inducible  NOS  (iNOS)  and  neuronal  NOS
(nNOS). Whereas eNOS and nNOS are usually
constitutively  expressed  under  physiological
conditions,  iNOS  can  be  induced  by  certain
stimuli,  including  hypoxia,  chemokines,  and
cytokines.3,4 Most of the NOS activity in the
heart corresponds to eNOS, which is located in
the vascular endothelium within the myocardi-
um, as well as in the cardiomyocytes.5 By con-
trast,  nNOS  appears  much  less  prominent,
being located in scattered nerves and ganglion
cells.6 Meanwhile,  iNOS  can  be  induced  in
macrophages, endothelial cells, and cardiomy-
ocytes5-7 in response to some stimuli, such as
hypoxia.4,8 
The study of NOS and the role of NO during
myocardial ischaemia/reperfusion has become
one of the fastest growing fields in basic car-
diovascular research in recent years. However,
the study of the cardiac NO/NOS system under
hypoxia/reoxygenation  has  been  scarcely
explored,  despite  the  great  interest  of  this
topic,  which  has  been  previously  taken  into
account by our group in the central nervous
system,9-11 the lung,12-15 and the heart.16 It has
been reported that hypoxia/reoxygenation may
influence NO production and tissue concentra-
tion, as well as eNOS and iNOS expression in
the heart.1,17 Nonetheless, a number of works
in  the  literature  have  shown  controversial
results regarding the changes that the cardiac
NO/NOS  system  undergoes  under  hypoxia/
reoxygenation.7,18-25 Hypoxia  resulting  from
ischaemia, haemorrhage or other cardiovascu-
lar problems is a common scenario in the clin-
ical practice of medicine, making the search
for useful remedies an essential effort. Thus,
the clarification of the behaviour of the cardiac
NO/NOS system under hypoxia/reoxygenation
is critical, since it could open the possibility of
future  studies  to  design  novel  therapies  for
hypoxia problems based on NO-pharmacology.
The study of the reoxygenation period is not
only quite novel, but also an essential way to
deal with these types of studies, since reoxy-
genation generally does not completely reverse
hypoxia-induced changes. 
Materials and Methods
Animals
The study was performed on mature adult
(4-5 months old) male albino Wistar rats kept
under standard conditions of light and temper-
ature and allowed ad libitum access to food
and water. All the experiments were conducted
according to E.U. guidelines on the use of ani-
mals for biochemical research (86/609/EU), as
well as to the Guiding Principles in the Care
and Use of Laboratory Animals, endorsed by
the American Physiological Society.
Experimental model
The acute hypobaric hypoxia was carried out
as  previously  published  by  our  group.10,26
Briefly, animals were placed in a chamber in
which  the  air  pressure  was  controlled  by
means of a continuous vacuum pump and an
adjustable inflow valve. Hypoxia was induced
by downregulating the environmental O2 pres-
sure to a final barometric pressure of 225 mm
Hg, resulting in a 48 mm Hg O2 partial pres-
sure (pO2). These conditions were maintained
for  30  min.  The  ascent  and  descent  speeds
were  kept  at  less  than  1000  feet/min,  with
duration of 30 min each (Figure 1). After the
hypoxia period, animals were kept under nor-
mobaric  normoxic  conditions  for  different
reoxygenation times (0, 2, 12, 24, 48, 72 h, and
5 days), and then sacrificed. Control animals
were sacrificed after being maintained for 30
min  in  the  chamber  under  normobaric  nor-
moxic conditions.  A total of 40 albino Wistar
rats  were  used  for  the  biochemical  experi-
ments  (5  animals  per  experimental  group).
The rats were sacrificed by cervical dislocation
and  the  hearts  were  immediately  removed,
rinsed in saline solution, and stored at -80°C
until  used.  Further  40  rats  were  used  for
immunohistochemistry (5 animals per experi-
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mental  group).  The  rats  were  anaesthetized
with Ketolar (1 mL/250 g weight, Parke Davis,
New York, NY, USA) by intraperitoneal injec-
tion and perfused in each reoxygenation peri-
od. Then, the hearts were removed, rinsed in
saline solution and fixed.
Quantitative Real-Time polymerase
chain reaction 
Total  heart  RNA,  isolated  using  Trizol
reagent  (Invitrogen,  Carlsbad,  CA,  USA)
according to the manufacturer's instructions,
was used for cDNA synthesis with Superscript
reverse transcriptase, as well according to the
manufacturer's  instructions.  Quantitative
Real-Time  polymerase  chain  reaction  (RT-
PCR)  was  carried  out  in  the  Mx3005PTM
(Stratagene, Cedar Creek, TX, USA) thermal
cycler.  Hypoxia  inducible  factor-1b (HIF-1b)
was used as the reference gene, since it is con-
stitutively  expressed  under  normoxic  and
hypoxic  situations.27,28 The  design  of  the
primers  was  performed  using  the  software
Primer 3. Sequences of used primers (forward,
reverse) were ATGGATGAGCCAACTCAAGG and
GGCTGCAGTCCTTTGATCTC for eNOS; AAGAG
TTCCCATCATTGCGT and TCCTCAACCTGCTC-
CTCACT  for  iNOS;  and  GCAGGATCAGAA-
CACAGCAA  and  ATGGTTACGGGAGGGGTAAG
for HIF-1b. 
Amplification  conditions  consist  of  initial
denaturing  (95°C,  10  min),  followed  by  45
cycles  of:  denaturing  (95°C,  30  s),  primer
annealing (60°C, 30 s), elongation (72°C, 30
s); and later 95°C (1 min), 55°C (30 s), and
95°C (30 s). All experiments were performed
in triplicates, and the values were used to cal-
culate the ratio of NOS to HIF-1b, with a value
of 1 used as the control (calibrator). The rela-
tive expression of NOS was calculated by the
2[−ʔʔC(T)] method.29
Western blot analysis
For Western blot analysis, equal amounts of
denatured  heart  total-protein  extracts  were
loaded  and  separated  in  7.5%  SDS-polyacry-
lamide gel. Proteins in the gel were transferred
to a PVDF membrane (Amersham Pharmacia
Biotech,  Buckinghamshire,  UK)  and  then
blocked.  Monoclonal  antibodies  to  eNOS
(1/800, BD Transduction Lab., Franklin Lakes,
NJ USA), iNOS (1/700, BD Transduction Lab.),
and  b-actin  (Sigma-Aldrich,  St.  Louis,  MD,
USA), as internal control, were used to detect
the respective proteins. Antibody reaction was
revealed by chemiluminescence detection fol-
lowing  the  manufacturer’s  recommendations
(ECL kit, Amersham Corp.). 
14C-L-Citrulline assay 
The enzymatic activity of the NOS isoforms
was measured in heart homogenates as the
rate of conversion of radiolabelled L-arginine
to  L-citrulline  in  the  assay  described  by
Radomski.30 Briefly, after homogenization and
centrifugation, the samples were incubated at
37ºC  with  [U14C]-L-arginine  (Amersham
Biosciences) in assay buffer (50 mM KH2PO4; 1
mM MgCl2; 0.2 mM CaCl2; 50 mM L-valine; 1
mM  L-citrulline;  20  mM  L-arginine;  0.1  mM
NADPH; 10 mM BH4; 0.1 M FAD; 0.1 M FMN,
and dithiotreitol 5 mM in Tris–HCl) (Sigma-
Aldrich).  The  addition  of  1  mM  L-NAME
(Sigma-Aldrich) was used to detect the reac-
tion background, while the addition of 2 mM
ethylene  glycol-bis  b-aminoethyl  ether
(Sigma-Aldrich), a Ca2+-chelator, was used to
differentiate between Ca2+-dependent (eNOS)
and Ca2+-independent (iNOS) activities.
After 20 min of incubation, the reaction was
stopped  by  adding  Dowex  50W-X  8-400  ion-
exchange  resin  (Sigma-Aldrich),  and  the
radioactivity  in  the  supernatant  was  deter-
mined in a liquid-scintillation counter (Wallac
1410, Pharmacia).
Immunohistochemistry
Hearts  were  fixed  with  paraformaldehyde
4% for 18 h, and then embedded in paraffin
(Paraplast Extra, Tyco Healthcare, Mansfield,
MA, USA). Sections were incubated for 30 min
with 10% serum of the animal in which the
secondary antibody was produced. Afterwards,
they were incubated first with diluted mono-
clonal  anti-iNOS  (1:600)  and  anti-eNOS
(1:400) antibodies (BD Transduction Lab.) in
PBS overnight at 4ºC, and later with a biotiny-
lated  secondary  antibody  (1:450;  Pierce
Biotechnology,  Inc.,  Rockford,  IL,  USA)  fol-
lowed by peroxidase-linked ABC. The peroxi-
dase activity was demonstrated following the
nickel-enhanced  diamino-benzidine  proce-
dure.31 Sections were mounted on slides, dehy-
drated, and covered using DPX. Controls for
background  staining  were  performed  by
replacing the primary antibody with PBS.
NO measurement
The reaction of NO with ozone results in
light emission, and this light (emitted in pro-
portion to the NO concentration) is the basis
for one of the most accurate NO assays avail-
able.32,33 NO production was indirectly quanti-
fied by measuring nitrate/nitrite and S-nitroso
compounds (NOx) using an ozone chemilumi-
nescence-based  method.  For  this  technique,
hearts  were  homogenized  in  PBS  with  pro-
tease inhibitors. Homogenates were then son-
icated,  centrifuged,  and  deproteinized  with
NaOH  0.8  N  and  ZnSO4 16%  solutions.  The
total amount of NOx was determined by a mod-
ification26 of  the  procedure  described  by
Braman  and  Hendrix34 using  a  NO  analyser
(NOA™  280i  Sievers  Instruments,  Boulder,
CO, USA). A saturated solution of vanadium
chloride (VCl3) in 1M HCl was added to the
nitrogen-bubbled  purge  vessel  fitted  with  a
cold-water condenser and a water jacket to per-
mit heating of the reagent to 90°C, using a cir-
culating bath. HCl vapours were removed by a
gas bubbler containing 1M NaOH. The gas-flow
rate in the detector was controlled by a needle
valve  adjusted  to  yield  a  constant  pressure.
Once the detector signal was stabilized, sam-
ples  were  injected  into  the  purge  vessel  to
react with the reagent, converting NOx to NO,
which  was  then  detected  by  ozone-induced
chemiluminescence. NOx concentrations were
calculated by comparison with standard solu-
tions of sodium nitrate. Final NOx values were
referred to the total protein concentration in
the initial extracts.
Statistical analysis
Data were expressed as mean ± SD (stan-
dard  deviation).  The  statistical  treatment  to
evaluate significant differences between groups
was performed with SPSS 15.0 software. The
data followed a normal distribution (tested with
Kolmogorov-Smirnov test) and the principle of
homoscedasticity  of  variances  (tested  with
Levene  test),  and  were  tested  by  a  one-way
ANOVA. The degree of statistical significance
was  established  by  applying  an  unpaired
Student’s t-test to compare differences between
means. The statistically significant differences
Original paper
Figure 1. Experimental model of hypoxia/reoxygenation. [page 92] [European Journal of Histochemistry 2011; 55:e17]
vs.  the  control  group  were  expressed  as
*P<0.05; **P<0.02; ***P<0.01; ****P<0.001.
Results
NOS mRNA expression
The  quantitative  analysis  of  eNOS  mRNA
expression (Figure 2A) showed a statistically
significant  increase  at  0  h  post-hypoxia
(P<0.02). On the other hand, iNOS mRNA lev-
els (Figure 2B) significantly rose at the onset
of reoxygenation (0 h: P<0.001). 
NOS protein expression
The  eNOS  protein  expression  (140-kDa)
significantly increased from 0 h to 12 h post-
hypoxia  (0  h:  P<0.01;  2  h:  P<0.001;  12  h:
P<0.001).  From  this  time  point  on,  eNOS
expression appeared to recover to baseline lev-
els,  which  were  maintained  until  5  days  of
reoxygenation (Figure 3A). It was barely possi-
ble to detect iNOS protein in the heart of con-
trol  animals  (Figure  3B).  Nevertheless,  this
NOS isoform (130-kDa) was induced in all the
experimental groups after hypoxia (0 h, 2 h, 12
h, 24 h, 48 h, 72 h, and 5 days: P<0.001).  
NOS activity 
The constitutive NOS enzymatic activity sig-
nificantly rose at 0 h (P<0.05), 2 h (P<0.001)
and 12 h (P<0.001) of reoxygenation (Figure
4A). On the other hand, iNOS activity signifi-
cantly augmented throughout the post-hypoxia
period (0 h: p<0.05; 2 h, 12 h, 24 h: p<0.001; 48
h, 72 h, 5 days: P<0.05) (Figure 4B).
NOS immunohistochemistry
In  all  the  experimental  groups,  eNOS
immunoreactivity  was  detected  in  vascular
endothelial cells and cardiomyocytes (Figure
5).  As  reflected  in  Figure  6,  no  iNOS
immunoreactivity could be detected in the con-
trol group. Nevertheless, iNOS-positive stain-
ing appeared in the myocardium after hypoxia
(0 h, 12 h, 5 days). Here, we show only the
most representative images of eNOS and iNOS
tissue  location,  corresponding  to  4  of  the  8
experimental groups. Magnification of eNOS
and  iNOS  positive  structures  is  shown  in
Figure 7, in order to allow easily identifying
eNOS and iNOS immunoreactive cells. 
NO production
Figure  8  shows  the  determinations  of
nitrate/nitrite and other S-nitroso compounds
(NOx) in the different experimental groups.
NOx levels significantly rose at 0 h post-hypox-
ia (P<0.001) in the heart homogenates. After
rising initially, NOx levels began to fall until
reaching values even lower to those of the con-
trol group after 5 d of reoxygenation.
Discussion
The  study  of  cardiac  hypoxia-associated
changes is complicated and elusive, although
conspicuously significant. The reoxygenation
eventually does not completely reverse hypox-
ia-induced changes, making crucial the study
of  the  subsequent  reoxygenation  period  to
understand the overall effects of hypoxia on
the heart. 
Hypoxia/reoxygenation has been reported to
influence NO production and NOS expression
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Figure 2. Effect of hypoxia/reoxygenation on NOS (nitric oxide synthase) isoforms mRNA
expression in heart of adult rats. Real-time PCR analysis of eNOS (A) and iNOS (B).
Experimental groups: control (C), and 0, 2, 12, 24, 48, 72 h, and 5 days (5d) post-hypox-
ia. Results were expressed as arbitrary units. Results are mean values of three independent
experiments and five animals per group. The statistically significant differences vs. the
control group were expressed as *P<0.05; **P<0.02; ***P<0.01; ****P<0.001.
Figure 3. Effect of hypoxia/reoxygenation on NOS (nitric oxide synthase) isoforms pro-
tein expression in heart of adult rats. Western blot analysis of eNOS (A) and iNOS (B).
Top panels: densitometric quantification of NOS isoforms in the different experimental
groups (Control (C), and 0, 2, 12, 24, 48, 72 h, and 5 days post-hypoxia), expressed as
arbitrary units (A.U.). Results are mean values of five independent experiments and five
animals per group. Bottom panels: representative autoradiography of the five determina-
tions of the corresponding eNOS and iNOS bands; b-actin immunodetection was includ-
ed as a protein-loading control. The statistically significant differences vs. the control
group were expressed as *P<0.05; **P<0.02; ***P<0.01; ****P<0.001.
Figure 4. Effect of hypoxia/reoxygenation on NOS (nitric oxide synthase) enzymatic
activity  in  heart  of  adult  rats.  14C-L-Citrulline  assay  for  constitutive  NOS  (A)  and
inducible NOS (B). Experimental groups: Control (C), and 0, 2, 12, 24, 48, 72 h, and 5
days post-hypoxia. Results were expressed as pmol/min/mg protein. Results are mean val-
ues of three independent experiments and five animals per group. The statistically signif-
icant differences vs. the control group were expressed as *P<0.05; **P<0.02; ***P<0.01;
****P<0.001.[European Journal of Histochemistry 2011; 55:e17] [page 93]
in the heart. Nonetheless, a number of works
have shown controversial results regarding the
changes  that  the  cardiac  NO/NOS  system
undergoes under such situations. Hence, the
present work aims to clarify the behaviour of
this  system  in  the  heart  submitted  to
hypoxia/reoxygenation.
Our  results  show  that  our  model  of
hypoxia/reoxygenation  significantly  raised
eNOS and iNOS mRNA and protein levels, as
well as enzymatic activity at the onset of reoxy-
genation, implying that 0 h post-hypoxia is a
crucial  moment  in  the  changes  that  the
NO/NOS  system  undergoes  during  cardiac
hypoxia/reoxygenation. We show that after ris-
ing initially, mRNA levels begin to fall after the
hypoxic stimulus, although the higher protein
levels persisted during the reoxygenation peri-
od. In this way, the results reflect raised eNOS
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Figure 5. (A-D) Histological sections of rat heart stained for eNOS immunohistochem-
istry. eNOS immunoreactivity was detected in endothelial cells (arrows) and cardiomy-
ocytes (arrow heads) in all the experimental groups: Control (C), and 0 h, 12 h, and 5 days
(5d) post-hypoxia. Scale bars: 50 µm.
Figure 6. (A-D) Histological sections of rat heart stained for iNOS immunohistochem-
istry.  No  iNOS  immunoreactivity  could  be  detected  in  the  control  group  (C).
Nevertheless, iNOS-positive staining appeared in endothelial cells (arrows) and cells in
myocardium (arrow heads) after hypoxia (0 h, 12 h, and 5 days (5d) post-hypoxia). Scale
bars: 50 µm.
Figure 7. Histological sections of rat heart
stained  for  eNOS  (A)  and  iNOS  (B)
immunohistochemistry.  Magnification  of
eNOS (A) and iNOS (B) positive structures
after 12 h post-hypoxia (arrows: endothe-
lial  cells,  arrow  heads:  cardiomyocytes).
Scale bars: 10 µm.
Figure 8. Effect of hypoxia/reoxygenation
on  nitrate,  nitrite,  and  other  S-nitroso
compounds (NOx) in heart of adult rats.
Experimental groups: Control (C), and 0,
2, 12, 24, 48, 72 h, and 5 days post-hypox-
ia. Results were expressed as µmol/mg pro-
tein. Results are mean values of three inde-
pendent experiments and five animals per
group. The  statistically  significant  differ-
ences vs. the control group were expressed
as  *P<0.05;  **P<0.02;  ***P<0.01;
****P<0.001.[page 94] [European Journal of Histochemistry 2011; 55:e17]
mRNA levels at 0 h post-hypoxia, while the pro-
tein increased from 0 h to 12 h of reoxygena-
tion. On the other hand, we detected a 2.5-fold
increase in iNOS mRNA immediately after the
hypoxic  insult,  while  iNOS  protein  was
induced throughout the reoxygenation period.
In fact, numerous pathophysiological stimuli,
including  hypoxia,  have  been  identified  to
modulate  NOS  expression  via  mechanisms
that  alter  steady-state  NOS  mRNA  levels.
These mechanisms involve changes in the rate
of NOS gene transcription, as well as alteration
of NOS mRNA processing and stability.35,36 Our
results suggest that hypoxia may boost NOS
mRNA levels at the onset of reoxygenation as a
cardiac response to hypoxic stress. We show
that  hypoxia-activated  expression  of  NOS
mRNA at 0 h fell to physiological levels during
the subsequent reoxygenation period, imply-
ing that once its function (translation to pro-
tein) was concluded, mRNA was degraded until
reaching basal values after 2 h post-hypoxia.
Raised mRNA levels are not usually needed for
a long time period, since proteins can remain
longer in the cells if they are required. In this
regard, elevated eNOS and iNOS protein levels
have been detected in the later post-hypoxia
times,  implying  an  important  role  for  these
proteins in the changes occurring during car-
diac hypoxia/reoxygenation. 
The  behaviour  of  NOS  isoforms  under
hypoxia has long been controversial, probably
due to the severity and duration of the hypoxia
model, the enormous intrinsic complication of
the  NO/NOS  system  regulation,  and  the
species and tissue studied. In agreement with
our  results,  some  authors  have  shown  that
eNOS  increases  in  the  hypoxic  heart,19,21
whereas  other  studies  have  reported  that
myocardial hypoxia/reoxygenation is associat-
ed with a decrease in eNOS.1,22One of the most
accepted mechanisms by which hypoxia could
increase eNOS expression is based on the fact
that hypoxia can activate the transcription of a
reporter gene under control of the eNOS 5’-
flanking region.37 In addition, Hoffman et al.
suggested that activation of the redox-sensi-
tive  activator  protein-1  transcription  factor
during hypoxia might be responsible for the
increase  in  eNOS  expression.38 Regarding
iNOS,  while  some  authors  have  reported  a
greater expression in the hypoxic rat heart,7,8,25
others have shown that iNOS is substantially
downregulated by hypoxia in the ventricles.19
Moreover, it has been reported that hypoxia
alone has no effect on iNOS gene expression,
or protein induction in cardiomyocytes.20 The
inconsistency  of  these  results  concerning
eNOS and iNOS expression may be due to dif-
ferences in the experimental protocol used, or
to the cardiac cell types examined. In addition,
those studies investigated only the time imme-
diate  after  hypoxia,  not  the  reoxygenation
period, as we do in this work. The most accept-
ed hypothesis to explain how hypoxia increas-
es  iNOS  expression  involves  the  hypoxia
inducible  factor-1  (HIF-1),  a  central  compo-
nent of the oxygen-sensing system that coordi-
nates cellular responses under conditions of
decreased oxygen availability.8 The iNOS pro-
moter contains a hypoxic responsive element,
and  HIF-1  could  bind  this  element  under
hypoxic situations to increase iNOS transcrip-
tion.39,40
There is also great debate concerning the
constitutive/inducible character of iNOS in the
healthy heart. In this respect, some authors
have described inducible NOS in normal car-
diac tissue,41,42 while others have failed to find
iNOS in healthy hearts.6,8 We did not succeed
in detecting this isoform in histological sec-
tions  of  control  rat  heart.  Contrarily,  iNOS
immunostaining  has  been  reported  in  car-
diomyocytes,41 and  the  endothelium  of  coro-
nary  vessels42 in  control  rats.  Nevertheless,
iNOS-positive  staining  appeared  in  the
myocardium  during  the  post-hypoxia  period.
Our results have also shown no iNOS protein
expression  in  the  control  group,  although
there was a basal mRNA expression. In this
regard, human primary cardiomyocytes in cell
culture express iNOS mRNA, but no iNOS pro-
tein.  The  inability  of  the  cardiomyocytes  to
translate iNOS mRNA was correlated with the
presence of the 5’- or 3’-UTR of the human
iNOS mRNA.43 Our findings support the con-
tention that the translation of iNOS mRNA in
the healthy heart is not necessary, since there
is a basal NO production, derived mainly from
eNOS, to maintain the normal blood flow under
physiological conditions. Nevertheless, a basal
iNOS mRNA expression could be required in
emergency conditions for exerting a key role
during  such  situations.  In  this  sense,  our
results show that after the hypoxic stimulus,
iNOS was induced throughout the reoxygena-
tion period, indicating major involvement of
this isoform in the changes that occur during
cardiac  hypoxia/reoxygenation.  In  fact,  in  a
recent work using the selective iNOS inhibitor
N-(3-(aminomethyl)benzyl)  acetamidine  or
1400W, we have proposed that iNOS may have
a  protective  effect  in  the  rat  heart  against
hypoxia/reoxygenation  injuries,  challenging
the conventional wisdom that this isoform is
deleterious under such conditions.16
The constitutive NOS enzymatic activity sig-
nificantly rose from 0 h to 12 h of reoxygena-
tion, coinciding with raised eNOS protein lev-
els. From these data, it may be assumed that
the majority of the constitutive NOS activity in
the  heart  corresponds  to  eNOS,  detected  in
vascular endothelial cells and cardiomyocytes.
In  this  regard,  it  is  well-known  that  nNOS
expression  is  much  less  prominent  in  this
organ.6 Moreover,  it  has  been  reported  that
hypoxia has no significant impact on cardiac
nNOS  expression  (mRNA  and  protein).24 In
short, our results have shown a significant rise
in eNOS mRNA, protein and activity, as well as
in  NOx  levels  immediately  after  hypoxia.  In
addition,  eNOS  protein  levels  and  activity
remained higher until 12 h of reoxygenation,
suggesting an emergency function of cardiac
NO/eNOS system at the earliest post-hypoxia
times.  In  this  sense,  the  increased  eNOS-
derived NO at the onset of reoxygenation may
exert a vasodilator effect in order to regulate
the blood flow through the hypoxic tissues. On
the  other  hand,  iNOS  activity  was  induced
throughout  the  post-hypoxia  period,  also
matching  with  augmented  iNOS  protein
expression. In agreement, hypoxia/reoxygena-
tion has been reported to markedly increase
iNOS activity in cardiomyocytes.1 However, the
rise in NOS enzymatic activity at the onset of
reoxygenation  contrasts  with  other  works
reporting that during hypoxia, low oxygen ten-
sions  can  limit  NOS  activity.44 In  fact,  early
studies  in  humans  found  that  NOS  activity
varies in direct proportion to oxygen levels.45
These controversial results may be due to the
different  times  in  which  the  NOS  activity
measurements were made. In this work, we
determined NOS enzymatic activities after the
descent post-hypoxia time (30 min), when oxy-
gen  increases  progressively  until  reaching
normobaric normoxic levels. 
The  question  whether  increased  NOS
expression leads to higher NO production in
vivo is  controversial.46 Our  results  indicate
that  hypoxia/reoxygenation  significantly
raised  NO  levels,  indirectly  quantified  by
nitrate/nitrite  and  S-nitroso  compounds
(NOx), just after the hypoxic stimulus. This
result coincides with significantly augmented
eNOS and iNOS expression, suggesting that
both isoforms would contribute to the higher
NOx  levels  at  the  onset  of  reoxygenation.
However, it is feasible that this greater NO pro-
duction could also be supported by the NO-stor-
age molecules. These molecules constitute a
NOS-independent  generation  of  NO  in  vivo,
and can scavenge or supply NO under emer-
gency  conditions.47-49 In  agreement  with  our
results,  some  previous  works  demonstrated
that  hypoxia  increased  NO  in  cardiomy-
ocytes,18,22,25 and  in  cardiac  microvessel
endothelial  cells.22,25 On  the  opposite,  other
authors found that hypoxia did not change NO
production in cardiomyocytes.20 The reason for
the variability in NO levels in these studies is
unclear, but may reflect differences in the car-
diac cell types analysed, the different experi-
mental model of hypoxia used, or the duration
and  severity  of  the  hypoxic  exposures.
Additionally, these studies examined only the
onset of reoxygenation, not the post-hypoxia
period, as we do in this work. Interestedly, our
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results also show a non-significant decrease in
NOx levels at the later reoxygenation times,
despite that NOS activity and expression were
enhanced. These unexpected results could be
explained  in  part  taking  into  account  that
eNOS protein levels and activity fell after 12 h
of reoxygenation until reaching physiological
levels. Also iNOS protein expression begin to
decrease after 12 h post-hypoxia, as well as the
enzymatic activity, suggesting that the involve-
ment of both NOS isoforms in the heart during
the final reoxygenation times may be no longer
needed. Additionally, the intense NO storage
occurring  in  the  vascular  wall,  which  could
mask a portion of NO, needs to be considered.50
In this regard, as mentioned above, NO can be
stored in the form of haemoglobin in red blood
cells, nitrosoglutathione, dinitrosyl iron com-
plexes or S-nitrosothiols, and can subsequent-
ly  be  released  from  these  complexes.
Furthermore, it is well known that the reoxy-
genation of the hypoxic cardiac tissue is char-
acterized  by  an  increase  in  reactive  oxygen
species (ROS) and reactive nitrogen species
(RNS), resulting in widespread lipid peroxida-
tion, protein oxidative and nitrosative modifi-
cations, and cellular apoptosis and necrosis.51
Peroxynitrite,  formed  by  the  reaction  of  NO
and superoxide, is a ROS and RNS that can
alter  protein  function  by  nitrating  phenolic
rings,  including  tyrosine,  to  create  nitroty-
rosines.52 In this way, it is also worth mention-
ing that a part of NO could derive in protein
nitration throughout the reoxygenation period
in the hypoxic heart. Indeed, we have recently
reported that our model of hypoxia/reoxygena-
tion boosted the levels of nitrotyrosine-modi-
fied proteins in the rat heart during all the
post-hypoxia period, especially at 12 h.16 
All  these  findings  indicate  that
hypoxia/reoxygenation processes alter NO lev-
els, as well as eNOS and iNOS expression and
activity in the rat heart. We have identified a
pattern  of  NOS  regulation,  reflecting  that
these  two  NOS  isoforms  are  upregulated  in
this organ, not only under short-term hypoxia,
but also during the subsequent reoxygenation
period. Given the multiple actions of NO on ion
channel activation, regulation of intracellular
calcium,  phosphorylation  of  contractile  pro-
teins,  and  induction  of  apoptotic  mecha-
nisms,53-56 NOS-derived NO would be expected
to have an important physiologic role in the
hypoxic rat heart. In this sense, it could be pro-
posed  that  just  after  the  hypoxic  stimulus,
NOS-derived NO levels rise to exert a vasodila-
tor effect in order to regulate the maintenance
of  blood  flow  through  the  hypoxic  tissues.
Thus, all the changes that the NO/NOS system
undergoes  during  hypoxia/reoxygenation
could be involved in the adaptation of the heart
to such situations. It is noteworthy that all the
parameters analysed increased at the onset of
reoxygenation, implying a crucial moment in
the changes occurring in the heart in response
to hypoxia/reoxygenation. Moreover, the study
of  the  subsequent  reoxygenation  period
reflects changes in the NO/NOS system until 5
days after hypoxia, showing that reoxygena-
tion really does not completely reverse hypox-
ia-induced changes. These findings reveal the
enormous  intrinsic  complication  of  the
NO/NOS  system  regulation  under  cardiac
hypoxia/  reoxygenation.  This  is  a  necessary
study revealing the behaviour of the NO/NOS
system under hypoxia and the later reoxygena-
tion period in the heart, as the basis for further
research on this field. In this way, we have pre-
viously  investigated  the  changes  in  the
NO/NOS system during such situations in the
rat lung, showing that eNOS increased only at
the onset of reoxygenation, while iNOS aug-
mented  at  the  final  post-hypoxia  times.
Moreover, dissimilar to what happens in the
heart,  the  normoxic  lung  showed  an  iNOS
baseline expression.12 Therefore, the present
work  confirms  that  the  changes  of  NO/NOS
system during hypoxia/reoxygenation depends
directly on the organ involved. In conclusion,
these data taken all together support the idea
of  regional  variability  in  NO/NOS  system
expression during systemic hypoxia. 
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